RT Journal Article SR Electronic T1 Tumor genomic profiling guides metastatic gastric cancer patients to targeted treatment: The VIKTORY Umbrella Trial JF Cancer Discovery JO Cancer Discov FD American Association for Cancer Research SP CD-19-0442 DO 10.1158/2159-8290.CD-19-0442 A1 Lee, Jeeyun A1 Kim, Seung Tae A1 Kim, Kyung A1 Lee, Hyuk A1 Kozarewa, Iwanka A1 Mortimer, Peter GS A1 Odegaard, Justin I A1 Harrington, Elizabeth A A1 Lee, Juyoung A1 Lee, Taehyang A1 Oh, Sung Yong A1 Kang, Jung-Hun A1 Kim, Jung Hoon A1 Kim, Youjin A1 Ji, Jun Ho A1 Kim, Young Saing A1 Lee, Kyoung Eun A1 Kim, Jinchul A1 Sohn, Tae Sung A1 An, Ji Yeong A1 Choi, Min-Gew A1 Lee, Jun Ho A1 Bae, Jae Moon A1 Kim, Sung A1 Kim, Jae J. A1 Min, Yang Won A1 Min, Byung-Hoon A1 Kim, Nayoung K.D. A1 Luke, Sally A1 Kim, Young Hwa A1 Hong, Jung Yong A1 Park, Se Hoon A1 Park, Joon Oh A1 Park, Young Suk A1 Lim, Ho Yeong A1 Talasaz, AmirAli A1 Hollingsworth, Simon J. A1 Kim, Kyoung-Mee A1 Kang, Won Ki YR 2019 UL http://cancerdiscovery.aacrjournals.org/content/early/2019/07/17/2159-8290.CD-19-0442.abstract AB The VIKTORY (targeted agent eValuation In gastric cancer basket KORea) trial was designed to classify metastatic GC patients based on clinical sequencing and focused on eight different biomarker groups (RAS aberration, TP53 mutation, PIK3CA mutation/amplification, MET amplification, MET overexpression, all negative, TSC2 deficient, or RICTOR amplification) to assign patients to one of the 10 associated clinical trials in second-line (2L) treatment. Capivasertib (AKT inhibitor), savolitinib (MET inhibitor), selumetinib (MEK inhibitor), adavosertib (WEE1 inhibitor), and vistusertib (TORC inhibitor) were tested with or without chemotherapy. 772 GC patients were enrolled and sequencing was successfully achieved in 715 patients (92.6%). When molecular screening was linked to seamless immediate access to parallel matched trials, 14.7% of patients received biomarker-assigned drug treatment. The biomarker-assigned treatment cohort had encouraging response rates and survival when compared to conventional 2L chemotherapy. ctDNA analysis demonstrated good correlation between high MET copy number by ctDNA and response to savolitinib.